Hanmi, HHP license oral drug delivery compound to Gilead
PositiveFinancial Markets

Hanmi Pharmaceutical and HHP have licensed an innovative oral drug delivery compound to Gilead, marking a significant advancement in drug formulation technology. This collaboration is expected to enhance the effectiveness of treatments and improve patient compliance, which is crucial in the pharmaceutical industry. The partnership not only showcases Hanmi's commitment to innovation but also strengthens Gilead's portfolio, potentially leading to better health outcomes for patients.
— Curated by the World Pulse Now AI Editorial System